Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis

Rheumatic Disease Clinics of North America

Volumn 29, Issue 2, 2003, Pages 409-426

  Lin, Antony T H ^a   Clements, Philip J ^a   Furst, Daniel E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALPHA INTERFERON; AMINOBENZOIC ACID; ANTIRHEUMATIC AGENT; BOSENTAN; BOVINE COLLAGEN TYPE 1; CAPTOPRIL; CHLORAMBUCIL; COLLAGEN TYPE 1; CYCLOFENIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE ANTIBODY; DIMETHYL SULFOXIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FLUOROURACIL; GAMMA INTERFERON; KETOTIFEN; METHOTREXATE; PENICILLAMINE; PREDNISOLONE; PREDNISONE; PROSTACYCLIN; RELAXIN; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG; UNIPROST;

ABDOMINAL CRAMP; ARTHRALGIA; AUTOIMMUNITY; BLOOD VESSEL INJURY; BONE MARROW SUPPRESSION; CEREBELLAR ATAXIA; CHILL; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE SEVERITY; EXERCISE; FATIGUE; FEVER; FLU LIKE SYNDROME; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HUMAN; INFUSION PUMP; INJECTION PAIN; KIDNEY DISEASE; KIDNEY FUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LUNG FIBROSIS; LUNG FUNCTION TEST; MORTALITY; MULTIPLE ORGAN FAILURE; MYALGIA; NAUSEA; NEPHROTOXICITY; PAIN; PARENTERAL NUTRITION; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RENOVASCULAR HYPERTENSION; REVIEW; SCORING SYSTEM; SKIN MANIFESTATION; SKIN TOXICITY; STEM CELL TRANSPLANTATION; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; VOMITING;

EID: 0038461984     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(03)00026-7     Document Type: Review

References (51)

1. White B, Bauer EA, Goldsmith LA, et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. Arthritis Rheum 1995;38(3):351-60.
2. Clements PJ, Hurwitz EL, Wong WK, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000;43(11):2445-54.
3. Steen VD, Medsger Jr TA, Rodnan GP, D-penicillamine therapy in progressive systemic sclerosis (scleroderma). Ann Intern Med 1982;97:652-9.
4. Furst DE, Clements PJ, Hillis S, et al. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Arthritis Rheum 1989;32:584-93.
5. Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42(6):1194-203.
6. Rook AH, Freundlich B, Jegasothy BV, et al. Treatment of systemic sclerosis with extracorporeal photochemistherapy. Arch Dermatol 1992;128:337-46.
7. Clements PJ, Wong WK, Hurwitz EL, et al. Correlates of the disability index of the Health Assessment Questionnaire. A measure of functional impairment in systemic sclerosis (SSc). Arthritis Rheum 1999;42:2372-80.
8. Clements PJ, Wong WK, Hurwitz EL, et al. The disability index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose vs low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum 2001;44:653-61.
9. Weisman IM, Zeballos RJ. Clinical exercise testing. Clin Chest Med 2001;22(4):679-701.
10. Demers C, McKelvie RS, Negassa A. Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure. Am Heart J 2001;142(4):698-703.
11. Furst DE. Rational therapy in the treatment of systemic sclerosis. Curr Opin Rheumatol 2000;12(6):540-4.
12. Rubens C, Ewert R, Halank M, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001;120(5):1562-9.
13. Badesch DB, Orton EC, Zapp LM, et al. Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension. Am J Respir Cell Mol Biol 1989;1:489-98.
14. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132(6):425-34.
15. Wax D, Garofano R, Barst RJ. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension. Chest 1999;116:914-20.
16. Galie N, Manes A, Branzi A. Medical therapy of pulmonary hypertension. The prostacyclin. Clin Chest Med 2001;22(3):529-37.
17. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165(6):800-4.
18. Channick RN, Simonnea G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001;358:1119-23.
19. Rubin LF, Badesch DB, Barst RJ. Bosentan therapy for pulmonary arterial hypertension. NEJM 2002;346:896-903.
20. Iwabuchi H, Kasama T, Hanaoka R. Downregulation of intercellular adhesion molecule-1 expression on human synovial fibroblasts by endothelin-1. J Rheumatol 1999;26(3):522-31.
21. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am 1996;22(4):861-78.
22. Zawada Jr ET, Clements PJ, Furst DA, et al. Clinical course of patients with scleroderma renal crisis treated with captopril. Nephron 1981;27:74-8.
23. Thurm RH, Alexander JC. Captopril in the treatment of scleroderma renal crisis. Arch Intern Med 1984;144:733-55.
24. Beckett VL, Donadio JV, Brennan Jr LA, et al. Use of captopril as early therapy for renal scleroderma: A prospective study. Mayo Clin Proc 1985;60:763-71.
25. Steen VD, Costantino JP, Shapiro AP, et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990;113:352-7.
26. Steen VD, Medsger Jr TA. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000;17:600-3.
27. Silver RM, Warrick JH, Kinsella MB, et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993;20:838-44.
28. White B, Moore W, Wigley F, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Int Med 2000;132:947-54.
29. Van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35(4):364-72.
30. Pope J, Bellamy N, Seibold J, et al. A randomized controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.
31. Casas JA, Saway PA, Villarreal I, et al. 5-Fluorouracil in the treatment of scleroderma: a randomized, double-blind, placebo-controlled international collaborative study. Ann Rheum Dis 1990;49:926-8.
32. Binks M, Passweg JR, Furst D, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001;60(6):577-84.
33. Furst DE, McSweeney PA, Nash R, et al. High-dose immunosuppressive therapy with autologous stem cell transplantation for systemic sclerosis. Blood 2002;100:1602-10.
34. Furst DE. Stem cell transplantation for autoimmune disease: progress and problems. Curr Opin Rheumatol 2002;14:220-4.
35. McKown KM, Carbone LD, Bustillo J, et al. Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. Arthritis Rheum 2000;43(5):1054-61.
36. Grassegger A, Schuler G, Hessenberger G, et al. Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. British J Derm 1998;139:639-48.
37. Ziesche R, Hofbauer E, Wittman K, et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. NEJM 1999;341:264-9.
38. Polisson RP, Gilkeson GS, Pyun EH, et al. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. J Rheumatol 1996;23(4):654-8.
39. Black CM, Silman AJ, Herrick AI, et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999;42(2):299-305.
40. Seibold JR, Koran JH, Simons R, et al. Recombinant human relaxin in the treatment of scleroderma. Ann Intern Med 2000;132:871-9.
41. Denton CP, Abraham DJ. Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin 2001;13(6):505-11.
42. Siriwardena D, Khaw PT, King AJ, et al. Human antitransforming growth factor beta(2) monoclonal antibody-a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study. Ophthalmology 2002;109:427-31.
43. Furst DE, Clements PJ, Harris R, et al. Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine. Ann Rheum Dis 1979;38:356-61.
44. Beckett VL, Conn DL, Ruster V, et al. Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin. Arthritis Rheum 1984;27:1137-43.
45. Williams HJ, Furst DE, Dahl SL, et al. Double-blind, multi-center controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis. Arthritis Rheum 1985;28:308-14.
46. Gibson T, Graham R. Cyclofenil treatment of scleroderma - a controlled study. Br J Rheumatol 1983;22:218-23.
47. Blom-Bulow B, Berg K, Wilhelm RA, et al. Cyclofenil versus placebo in progressive systemic sclerosis. A one-year double-blind crossover study of 27 patients. Act Med Scand 1981;210:419-28.
48. Zarafonetis CJD, Dubach L, Skovronski JJ, et al. Retrospective studies in scleroderma: skin response to para-aminobenzoate therapy. Clin Exp Rheumatol 1988;6:261-8.
49. Clegg DO, Reading JC, Mayes MD, et al. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma. J Rheumatol 1994;21:105-10.
50. Gruber BL, Kaufman LD. A double-blind randomized controlled trial of ketotifen versus placebo in early diffuse scleroderma. Arthritis Rheum 1991;34:362-5.
51. Clements PJ, Lachenbruch PA, Sterz M, et al. Cyclosporine in systemic sclerosis: results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 1993;36(1):75-83.